Evaluation of Polymyxin B as a Novel Vaccine Adjuvant and Its Immunological Comparison with FDA-Approved Adjuvants
Mahek Gulani, Yash Harsoda, Tanisha Arte, Martin J. D’Souza, Priyal Bagwe, Emmanuel Adediran, Nigel D’Souza, Dedeepya Pasupuleti · 2025
Read Evaluation of Polymyxin B as a Novel Vaccine Adjuvant and Its Immunological Comparison with FDA-Approved Adjuvants by Mahek Gulani, Yash Harsoda, Tanisha Arte, Martin J. D’Souza, Priyal Bagwe, Emmanuel Adediran, Nigel D’Souza, Dedeepya Pasupuleti (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12737746.txt.
Description
Mahek Gulani and seven co-workers wrote a 2025 study on a known antibiotic as a possible vaccine booster. Boosters help vaccines raise a strong immune response. Most germs enter through moist body surfaces, so vaccines need to guard those sites. Few boosters are built for that route, though.
The team made tiny particles of the drug and paired them with several test vaccines. Lab checks found the particles did not kill key immune cells at tested doses. They sped up some cell cleanup tasks and raised immune signals. Marker tests showed signs of a stronger immune start. The work compares this booster with licensed ones.
Catalog record
| CREATOR | Mahek Gulani, Yash Harsoda, Tanisha Arte, Martin J. D’Souza, Priyal Bagwe, Emmanuel Adediran, Nigel D’Souza, Dedeepya Pasupuleti |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |